文献速递乳腺癌胸部肿瘤消化系统肿瘤

患者合并症与癌症临床试验参与的相关性

Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究基于嵌入多个癌症网站的在线治疗决策工具开展全国性调查,分析5499例在过去3个月内做出治疗决定的乳腺癌、肺癌、结直肠癌或前列腺癌患者。结果显示,存在1种或以上合并症与试验讨论、试验提供和试验参与的风险降低相关;取消ASCO推荐的合并症限制每年可能增加多达6317例患者试验注册。

要点

  • 合并症存在与试验讨论风险降低相关:44.1% vs 37.2%,OR 0.86(95%CI 0.75-0.97;P=0.02)。
  • 合并症存在与试验提供风险降低相关:21.7% vs 15.7%,OR 0.82(95%CI 0.70-0.96;P=0.02)。
  • 合并症存在与试验参与风险降低相关:11.3% vs 7.8%,OR 0.76(95%CI 0.61-0.94;P=0.01)。

核心结论

  • 独立于社会人口学变量,合并症的存在与试验讨论、试验提供及试验参与本身呈不利相关。
  • 更新试验入组标准可能为数千例合并症管理良好的患者每年提供参与临床试验的机会。

研究设计与样本

  • 全国性调查嵌入基于网络的癌症治疗决策工具,该工具可在多个癌症相关网站访问。
  • 参与者须已确诊乳腺癌、肺癌、结直肠癌或前列腺癌。
  • 共分析5499例在过去3个月内做出治疗决定的受试患者,采用逻辑回归分析和模拟。
  • 暴露因素为癌症诊断及18种合并症中的1种或以上。

主要发现

  • 5499例参与者中,女性3420例(62.6%),男性2079例(37.8%),平均年龄56.63岁(SD 10.05)。
  • 多数患者(65.6%;n=3610)有1种或以上合并症,最常见合并症为高血压(35.0%;n=1924)。
  • 与无合并症相比,有1种或以上合并症与试验讨论风险降低相关(44.1% vs 37.2%;OR 0.86;95%CI 0.75-0.97;P=0.02)。
  • 与无合并症相比,有1种或以上合并症与试验提供风险降低相关(21.7% vs 15.7%;OR 0.82;95%CI 0.70-0.96;P=0.02)。
  • 与无合并症相比,有1种或以上合并症与试验参与风险降低相关(11.3% vs 7.8%;OR 0.76;95%CI 0.61-0.94;P=0.01)。

关键数值与推荐

  • 美国临床肿瘤学会(ASCO)、癌症研究之友和美国食品药品监督管理局最近建议对常规用于排除患者参与癌症临床试验的合并症相关标准进行现代化更新。
  • 研究模拟显示,取消ASCO推荐的合并症限制每年可能产生多达6317例额外的患者试验注册。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The American Society of Clinical Oncology (ASCO), Friends of Cancer Research, and the US Food and Drug Administration recently recommended modernizing criteria related to comorbidities routinely used to exclude patients from cancer clinical trials. The goal was to design clinical trial eligibility such that trial results better reflect real-world cancer patient populations, to improve clinical trial participation, and to increase patient access to new treatments in trials. Yet despite the assumed influence of comorbidities on trial participation, the relationship between patients' comorbidity profile at diagnosis and trial participation has not been explicitly examined using patient-level data. OBJECTIVES: To investigate the association between comorbidities, clinical trial decision-making, and clinical trial participation; and to estimate the potential impact of reducing comorbidity exclusion criteria on trial participation, to provide a benchmark for changing criteria. DESIGN, SETTING, AND PARTICIPANTS: A national survey was embedded within a web-based cancer treatment-decision tool accessible on multiple cancer-oriented websites. Participants must have received a diagnosis of breast, lung, colorectal, or prostate cancer. In total, 5499 surveyed patients who made a treatment decision within the past 3 months were analyzed using logistic regression analysis and simulations. EXPOSURES: Cancer diagnosis and 1 or more of 18 comorbidities. MAIN OUTCOMES AND MEASURES: Patient discussion of a clinical trial with their physician (yes vs no); if a trial was discussed, the offer of trial participation (yes vs no); and, if trial participation was offered, trial participation (yes vs no). RESULTS: Of the 5499 patients who participated in the survey, 3420 (62.6%) were women and 2079 (37.8%) were men (mean [SD] age, 56.63 [10.05] years). Most patients (65.6%; n = 3610) had 1 or more comorbidities. The most common comorbid condition was hypertension (35.0%; n = 1924). Compared with the absence of comorbidities, the presence of 1 or more comorbidities was associated with a decreased risk of trial discussions (44.1% vs 37.2%; OR, 0.86; 95% CI, 0.75-0.97; P = .02), trial offers (21.7% vs 15.7%; OR, 0.82; 95% CI, 0.70-0.96; P = .02), and trial participation (11.3% vs 7.8%; OR, 0.76; 95% CI, 0.61-0.94; P = .01). The removal of the ASCO-recommended comorbidity restrictions could generate up to 6317 additional patient trial registrations every year. CONCLUSIONS AND RELEVANCE: Independent of sociodemographic variables, the presence of comorbidities is adversely associated with trial discussions, trial offers, and trial participation itself. Updating trial eligibility criteria could provide an opportunity for several thousand more patients with well-managed comorbidities to participate in clinical trials each year.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Unger JM, Hershman DL, Fleury ME, et al. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol. 2019. PMID: 30629092. doi:10.1001/jamaoncol.2018.5953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。